welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Sarepta Therapeutics and Jerry R. Mendell, M.D. to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program from the 23rd International Annual Congress of the World Muscle Society
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, and Jerry R. Mendell, M.D., Curran-Peters Chair of Pediatric Research and Professor of Pediatrics and Neurology, Nationwide Children’s Hospital and The Ohio State University; The Research Institute at Nationwide Children’s Hospital, will host a webcast conference call from the 23rd International Annual Congress of the World Muscle Society (WMS) in Mendoza, Argentina, on Thursday, October 4, 2018 at 7:00 a.m. Eastern Time / 8:00 a.m. local Argentina time. The call will focus on an update regarding Sarepta’s Duchenne muscular dystrophy (DMD) micro-dystrophin gene therapy program and will be led by Dr. Mendell, a renowned researcher in the field of DMD.
rareRelated
-
Duchenne Muscular Dystrophy Awaits Gene TherapySolid’s gene therapy disappoints in th...
-
NIH Awards $86 Million to Improve Genome Editing TechniquesSomatic Cell Genome Editing support is a...
-
Shape Therapeutics’s RNA Editing Gene Therapy Platform Focused on Curing Genetic DiseasesShape Therapeutics, Inc. (ShapeTx), a de...
-
International TREAT-NMD ConferenceWe are delighted to announce that our 6t...
-
Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular DystrophyDystrophinopathy is a disease continuum ...
-
The Clinical Development Program Studying RG6206 (RO7239361) in Duchenne Will be DiscontinuedWe are writing to share with you unfortu...
-
A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular DystrophyThis is a first-in-human/first-in-patien...
